Details of the Drug Combination

General Information of Drug Combination (ID: DCXPTRU)

Drug Combination Name
Indazole derivative 5 TEM
Indication
Disease Entry Status REF
Invasive ductal carcinoma Investigative [1]
Component Drugs Indazole derivative 5   DMM1I8R TEM   DMLNFWU
Small molecular drug Small molecular drug
2D MOL 2D MOL
3D MOL 3D MOL
High-throughput Screening Result Testing Cell Line: T-47D
Zero Interaction Potency (ZIP) Score: 4.82
Bliss Independence Score: 6.81
Loewe Additivity Score: 6
LHighest Single Agent (HSA) Score: 6.07

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)
Indazole derivative 5 Interacts with 2 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
ABL T315I mutant (ABL T315I) TTZJTWA ABL1_HUMAN Inhibitor [3]
Fusion protein Bcr-Abl T315I mutant (Bcr-Abl T315I) TTIV39N BCR_HUMAN-ABL1_HUMAN Inhibitor [3]
------------------------------------------------------------------------------------
Indication(s) of TEM
Disease Entry ICD 11 Status REF
Postherpetic neuralgia 1E91.5 Phase 2 [2]

Test Results of This Drug Combination in Other Disease Systems

Indication DrugCom ID Cell Line Status REF
Plasma cell myeloma DCVVLQT RPMI-8226 Investigative [4]
Colon adenocarcinoma DCJ9UAA COLO 205 Investigative [1]
Invasive ductal carcinoma DCNQZ7E BT-549 Investigative [1]
Adenocarcinoma DCV19MO DU-145 Investigative [5]
Adenocarcinoma DCCB258 HT29 Investigative [5]
Amelanotic melanoma DC7I5VT M14 Investigative [5]
High grade ovarian serous adenocarcinoma DCIJ9XK OVCAR-8 Investigative [5]
High grade ovarian serous adenocarcinoma DC39CXQ NCI\\/ADR-RES Investigative [5]
Lung adenocarcinoma DCLANZG HOP-62 Investigative [5]
Melanoma DCRHE85 SK-MEL-2 Investigative [5]
Melanoma DCE56V4 UACC-257 Investigative [5]
Ovarian serous cystadenocarcinoma DCVFD3V SK-OV-3 Investigative [5]
------------------------------------------------------------------------------------
⏷ Show the Full List of 12 DrugCom(s)

References

1 Biologically active neutrophil chemokine pattern in tonsillitis.Clin Exp Immunol. 2004 Mar;135(3):511-8. doi: 10.1111/j.1365-2249.2003.02390.x.
2 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800030055)
3 Bcr-Abl tyrosine kinase inhibitors: a patent review.Expert Opin Ther Pat. 2015 Apr;25(4):397-412.
4 Recurrent recessive mutation in deoxyguanosine kinase causes idiopathic noncirrhotic portal hypertension.Hepatology. 2016 Jun;63(6):1977-86. doi: 10.1002/hep.28499. Epub 2016 Mar 31.
5 Loss of function mutations in VARS encoding cytoplasmic valyl-tRNA synthetase cause microcephaly, seizures, and progressive cerebral atrophy.Hum Genet. 2018 Apr;137(4):293-303. doi: 10.1007/s00439-018-1882-3. Epub 2018 Apr 24.